Notice of CURES Fee Increase
Effective April 1, 2021, the Controlled Substance Utilization Review and Evaluation System (CURES) fee will increase from $6 to $11 annually for a period of two years. The increase will be applied to licenses expiring after July 1, 2021, and is assessed at the time of license renewal on specified licensees of DCA allied health boards that prescribe, order, administer, furnish, or dispense Schedule II, Schedule III, Schedule IV, or Schedule V controlled substances.
Most licensees will see a $22 CURES Fee due to the biennial renewal cycle. The fee covers the reasonable regulatory costs of the Department of Justice for operating and maintaining CURES, a critical element in the state’s effort to address the growing danger of opioid addiction stemming from prescription drug abuse.
For more information about CURES, visit: https://oag.ca.gov/cures.
NEW LAW EFFECTIVE JULY 1, 2021
Assembly Bill (AB) 528 (Low, Chapter 677, Statutes of 2019) expands access and use of the Controlled Substance Utilization Review and Evaluation System (CURES) effective July 1, 2021. Please see the Joint Bulletin for an update on implementation of system enhancements for delegates and non-Drug Enforcement Agency (DEA) practitioners.
For more information on the current requirements for consulting CURES, please refer to the CURES Mandatory Use Brochure.
NEW LAWS EFFECTIVE JANUARY 1, 2021
- Updated Prescription Pad Security Requirements - California state law requires 15 security elements, including a 12-character serial number and corresponding barcode, to appear on California Security Prescription Forms. State law also requires California Security Prescription Forms to be produced by printers approved by the California Department of Justice’s California Security Prescription Printers Program. To reduce potential negative impact to patients, prescribers and pharmacists are reminded of the provisions related to oral or electronically transmitted prescriptions for any controlled substance classified in Schedule III, IV and V, Health and Safety Code section 11164(b). Prescribers and pharmacists are encouraged to work together as appropriate to address the needs of patients in possession of noncompliant forms. For more information, please refer to the AB 149 Joint Statement.
- Revised Reporting Requirements for Controlled Substances – The dispensing of a controlled substance must be reported to the Controlled Substance Utilization Review and Evaluation System (CURES) within one working day after the medication is released to the patient or the patient’s representative. Previously, the deadline to report was seven days after dispensing. Further, this law requires reporting of Schedule V drugs, in addition to Schedules II, III, and IV. This requirement applies to pharmacists and prescribers who dispense controlled substances.
What is CURES?
The Controlled Substance Utilization Review and Evaluation System (CURES), maintained by the Department of Justice (DOJ), is a platform that tracks all Schedule II – V controlled substances dispensed to patients in California. Authorized prescribers, pharmacists, law enforcement, and regulatory agencies can view information in CURES including:
- patient name, date of birth, address
- prescriber name, DEA number
- pharmacy name, license number
- date prescription was dispensed
- prescription number
- drug name, quantity and strength
- number of refills remaining
For assistance with CURES 2.0 registration, access, or system use, contact the CURES helpdesk at CURES@doj.ca.gov or (916) 210-3187.
CURES Registration at a Glance
Registration is done through DOJ’s CURES 2.0 Registration. Only licensed California prescribers and dispensers can register with CURES. (NOTE: If you are with a law enforcement agency or regulatory board and need CURES access, please contact the CURES helpdesk at CURES@doj.ca.gov or (916) 210-3187).
To register, licensed prescribers and dispensers will need:
- A valid email address. This will be the exclusive email address to which CURES-related correspondence is sent.
- Your state license information. This information will be verified with the regulatory board issuing your license.
- Your federal DEA license information (prescribers only). This information will be verified with the Drug Enforcement Agency (DEA).
DOJ will process your registration application and send email notification of its approval or denial.
Once you receive DOJ email notification of your approved registration, you can access CURES 2.0 through DOJ’s CURES 2.0 Login. Reference the Prescriber and Dispenser User Guide for detailed information about navigating and using CURES 2.0.
Data Submission Requirements
For data submission instructions or assistance with transmission issues, please contact:
Atlantic Associates, Inc. – CURES Prescription Data Collection Vendor
Toll Free: (800) 539-3370
Phone: (603) 627-7829
Fax: (877) 508-6704
CURES Upgrade: CURES 2.0
On January 8, 2016, the DOJ released the CURES 2.0 system upgrade. This upgrade offers a significantly improved user experience and increased functionality:
- Allow approved delegates to run patient report queries for access by prescribers and dispensers
- Send peer-to-peer communications
- Receive patient alerts
For More Information
To learn more about CURES 2.0, visit the following links:
You must be registered to use CURES, even if you do not actively prescribe or dispense, if you are a:
- • California-licensed health care practitioner possessing a DEA number
- • California-licensed pharmacist with an active license
(California Health & Safety Code § 11165.1)